While the CD3+ and CD8+ tumor infiltrate was increased in the RGS-treated tumors, there was no significant alteration in the level of CD4+FoxP3+ T regulatory cells (Tregs) or angiogenesis (CD31) (Fig. 3 f). The gene discussed is FOXP3; the disease is neoplasm.